The MIT spinout has raised $19.4m from unnamed backers, and the plant-based ingredient developer will use the cash to expand its production capacity.

Manus Bio, a US-based natural ingredient supplier spun out from Massachusetts Institute of Technology (MIT), has secured $19.4m in a series A round backed by unnamed new and existing investors. Byron Alsberg, partner at venture capital firm 415 Investments, has joined Manus Bio’s board of directors together with Raymond Nobu Chang, managing director of angel…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.